Yissum Technology Transfer Company of the Hebrew University

Agrinnovate India Ltd. (AgIn) was incorporated under the Companies Act, 1956 (No. 1 of 1956) on 19th October, 2011. It is a "for profit" Company owned by Department of Agricultural Research & Education (DARE), Ministry of Agriculture, Government of India. It is to act as an effective interface between Indian Council of Agricultural Research (ICAR- an autonomous organization under DARE) on one side and the Stakeholders of agricultural sector (Farmers; Public & Private Sector firms; R&D organizations; Educational Institutions- all of these at National and International level) on the other side, for a significant purpose of securing, sustaining and promoting global agricultural development.

Avraham Pharmaceuticals Ltd. is a privately held pharmaceutical company based in Yavne, Israel, established in 2010. The company focuses on developing innovative treatments for neurodegenerative disorders. Its lead product candidate, Ladostigil, is aimed at addressing mild cognitive impairment and is designed to incorporate neuroprotective mechanisms, including the reduction of oxidative stress and microglial activation, as well as the inhibition of pro-inflammatory cytokines. Avraham Pharmaceuticals has raised $9 million to support a European Phase II proof-of-concept efficacy trial for Ladostigil in patients with Alzheimer's disease.

Avraham Pharmaceuticals Ltd. is a privately held pharmaceutical company based in Yavne, Israel, established in 2010. The company focuses on developing innovative treatments for neurodegenerative disorders. Its lead product candidate, Ladostigil, is aimed at addressing mild cognitive impairment and is designed to incorporate neuroprotective mechanisms, including the reduction of oxidative stress and microglial activation, as well as the inhibition of pro-inflammatory cytokines. Avraham Pharmaceuticals has raised $9 million to support a European Phase II proof-of-concept efficacy trial for Ladostigil in patients with Alzheimer's disease.

Avraham Pharmaceuticals Ltd. is a privately held pharmaceutical company based in Yavne, Israel, established in 2010. The company focuses on developing innovative treatments for neurodegenerative disorders. Its lead product candidate, Ladostigil, is aimed at addressing mild cognitive impairment and is designed to incorporate neuroprotective mechanisms, including the reduction of oxidative stress and microglial activation, as well as the inhibition of pro-inflammatory cytokines. Avraham Pharmaceuticals has raised $9 million to support a European Phase II proof-of-concept efficacy trial for Ladostigil in patients with Alzheimer's disease.

Avraham Pharmaceuticals Ltd. is a privately held pharmaceutical company based in Yavne, Israel, established in 2010. The company focuses on developing innovative treatments for neurodegenerative disorders. Its lead product candidate, Ladostigil, is aimed at addressing mild cognitive impairment and is designed to incorporate neuroprotective mechanisms, including the reduction of oxidative stress and microglial activation, as well as the inhibition of pro-inflammatory cytokines. Avraham Pharmaceuticals has raised $9 million to support a European Phase II proof-of-concept efficacy trial for Ladostigil in patients with Alzheimer's disease.

Chiasma, Inc. is a late-stage biopharmaceutical company based in Needham, Massachusetts, that specializes in developing oral medications for rare and serious chronic diseases. Utilizing its proprietary Transient Permeability Enhancer technology, Chiasma aims to transform injectable drugs into oral formulations, enhancing their absorption and potentially enabling new therapeutic indications. The company is currently focused on MYCAPSSA, an oral octreotide capsule designed for adult patients with acromegaly, a condition characterized by excessive growth hormone production. MYCAPSSA is undergoing Phase III clinical trials in the United States and is also in the process of seeking regulatory approval in the European Union. Founded in 2001, Chiasma is dedicated to improving treatment options for patients with debilitating conditions through innovative drug delivery methods.